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Emblica officinalis and its enriched tannoids delay streptozotocininduced diabetic cataract in rats
P. Suryanarayana,1 Megha Saraswat,1 J. Mark Petrash,2 G. Bhanuprakash Reddy1
1

Biochemistry Division, National Institute of Nutrition, Hyderabad, India; 2Department of Ophthalmology and Visual Sciences,
Washington University, St. Louis, MO
Purpose: Aldose reductase (AR) has been a drug target because of its involvement in the development of secondary
complications of diabetes including cataract. We have previously reported that the aqueous extract of Emblica officinalis
and its constituent tannoids inhibit AR in vitro and prevent hyperglycemia-induced lens opacification in organ culture.
The purpose of the current study was to investigate the effect of Emblica and its enriched tannoids on streptozotocin
(STZ)-induced diabetic cataract in rats.
Methods: Diabetes was induced in Wistar-NIN rats by STZ (35 mg/kg body weight, intraperitoneally) and the animals
were divided into three groups (Group II, III, and IV). The control rats (Group I) received only vehicle. While Group I and
Group II animals received AIN-93 diet, rats in Groups III and IV received 0.2% of standardized mixture of Emblica
tannoids and 2% of Emblica pericarp, respectively, in an AIN-93 diet for a period of eight weeks. Cataract progression due
to hyperglycemia was monitored by slit-lamp biomicroscope and classified into four stages. At the end of the eight weeks,
the animals were sacrificed and markers of the polyol pathway, oxidative stress, and alterations in protein content and
crystallin profile in the lens were measured. Blood glucose and insulin levels were also determined.
Results: Both Emblica and its tannoids did not prevent STZ-induced hyperglycemia as assessed by blood glucose and
insulin levels. However, slit lamp microscope observations indicated that these supplements delayed cataract progression.
The present studies suggest that Emblica and its tannoids supplementation inhibited AR activity as well as sorbitol formation in the lens. The results also point out that Emblica and its tannoids might counter the polyol pathway-induced oxidative stress as there was a reversal of changes with respect to lipid peroxidation, protein carbonyl content, and activities of
antioxidant enzymes. Emblica also prevented aggregation and insolubilization of lens proteins caused by hyperglycemia.
Conclusions: The results provide evidence that Emblica and an enriched fraction of Emblica tannoids are effective in
delaying development of diabetic cataract in rats.

A number of studies with experimental animals suggest
that the compounds that inhibit AR could be effective in the
prevention of certain diabetic complications [13-15]. To date,
a number of AR inhibitors (ARI) such as tolrestat, epalrestat,
zenarestat, zopolrestat, and sorbinil have been found to improve some diabetic complications in animal experiments and
have been developed to the point of clinical evaluation. Nonetheless, clinical trials of ARI against neuropathy and retinopathy have met with limited success and some of the synthetic
ARI were associated with deleterious side effects and poor
penetration of target tissues such as the nerve and retina [16,17].
Therefore, in recent years, there is increased interest in
identifying natural sources of ARIs that can be tested for their
therapeutic value against diabetic complications [18-20]. In
this context, we have been investigating the potential of spice/
dietary sources which include Emblica to prevent diabetic cataract in animals [21-24]. Emblica officinalis Gaertn., commonly
known as amla, is extensively used in many preparations of
Ayurveda (one of the systems of Indian traditional medicine)
and also against many chronic ailments including diabetes [2527]. We have previously reported that the aqueous extract of
Emblica inhibited AR and showed that the hydrolysable
tannoids present in Emblica are responsible for the inhibition
[22]. Furthermore, we also showed that tannoids of Emblica
prevented sugar-cataract in a lens organ culture system [22].

Diabetes mellitus is a heterogeneous metabolic disorder
characterized by high levels of blood glucose. Prolonged exposure to uncontrolled chronic hyperglycemia in diabetes can
lead to various complications in the eye including cataract and
retinopathy [1,2]. Cataract, characterized by cloudiness or
opacification of the eye lens, is the leading cause of blindness
all over the world. In view of the widespread prevalence of
diabetes in developing countries like India [3-5], diabetic cataract may pose a major problem in the management of blindness. Although the pathogenesis of diabetic complications is
not known, many biochemical pathways associated with hyperglycemia have been implicated [1]. Among these, the polyol
pathway has been extensively studied. Aldose reductase (AR)
is the first and rate-limiting enzyme of the polyol pathway
[6]. Under euglycemic conditions, AR plays a minor role in
glucose metabolism; however, during diabetes, its contribution is significantly enhanced [7,8] leading to a conversion of
excess glucose to sorbitol in insulin independent tissues like
the lens. AR dependent synthesis of excess polyols has been
implicated as one of the mechanisms leading to diabetic and
galactosemic cataracts [9-12].
Correspondence to: Geereddy Bhanuprakash Reddy, Ph.D., National
Institute of Nutrition, Hyderabad - 500 007, India; Phone: 91-4027008921; FAX: 91-40-27019074; email: geereddy@yahoo.com
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These results imply that constituents of Emblica may be explored as potential therapeutic agents against diabetic cataract. In the present study, we evaluated the efficacy of whole
Emblica pericarp and the enriched tannoid mixture for effectiveness in prevention or delay in the onset and progression of
cataracts in the streptozotocin (STZ)-induced diabetic rat
model.
METHODS
Materials: STZ, NADPH, NADH, 2-thiobarbituric acid
(TBA), 1,1,3,3-tetraethoxy propane (TEP), DL-glyceraldehyde, lithium sulfate, β-mercaptoethanol, glutathione, glutathione reductase, BSA, 2,4-dinitrophenylhydrazine (DNPH),
and EDTA were obtained from Sigma-Aldrich (St. Louis, MO).
All other chemicals and solvents were of analytical grade and
were obtained from local companies.
Preparation of Emblica pericarp powder: Fresh fruits of
Emblica were collected from September through October from
the local market. The pericarp of the fruit was freeze-dried.
The dried material was powdered and used for the experiment
by mixing it with an AIN-93 diet.
Standardized mixture of Emblica tannoids: Four
hydrolysable tannoids, emblicanin A, emblicanin B,
punigluconin, and pedunculagin have been isolated from
Emblica pericarp and their structures have been established
[28]. We have obtained the enriched fraction of E. officinalis
juice with the above tannoids as a standardized extract in the
powder form gratis from Indian Herbs Research & Supply
Company, Saharanpur, India. The relative proportions of different tannoids in the standardized extract are as follows
emblicanin A and B, 35-55%; punigluconin, 4-15%;
pedunculagin, 10-20%; rutin, 3%; and gallic acid, 1%.
Experimental design: Male, WNIN rats (two to three
months old) with an average body weight of 231±11 g (obtained from the National Center for Laboratory Animal Sciences, National Institute of Nutrition, Hyderabad, India) were
used in the study. Diabetes was induced in overnight-fasted
animals by a single intraperitoneal injection of STZ (35 mg/
kg) in 0.1 M citrate buffer, pH 4.5. Another set of rats, which
received only vehicle, served as the control (Group I; n=8).
Fasting blood glucose levels were measured 72 h after STZ
injection. Animals having blood glucose levels >145 mg/dL
were considered diabetic and were divided into three groups
(Group II, III, and IV). Animals in these groups received either only the AIN-93 diet (Group II; n=13) or received the
AIN-93 diet containing 0.2% tannoids mixture (Group III; n=9)
or 2.0% of Emblica powder (Group IV; n=9). Emblica contains 10-12% of tannoids and hence 0.2% tannoids corresponds
to approximately 2% Emblica. Animals were treated as described for a period of eight weeks and were housed in individual cages in a temperature- and humidity-controlled room
with a 12 h light-dark cycle. All animals had free access to
water. Food intake (daily) and body weights (weekly) were
monitored during the experiment. Animal care and protocols
were in accordance with and approved by the Institutional
Animal Ethics Committee and conformed to the ARVO State-

ment for the Use of Animals in Ophthalmic and Vision Research.
Slit lamp examination and cataract classification: Eyes
were examined every week using a slit lamp biomicroscope
(Kowa Portable, Japan) on dilated pupils. Initiation, progression, and maturation of lenticular opacity was graded into five
stages as follows: stage 0 - clear lenses and no vacuoles present;
stage 1 - vacuoles cover approximately one-half of the surface of the anterior pole forming a sub capsular cataract; stage
2 - some vacuoles have disappeared and the cortex exhibits a
hazy opacity; stage 3 - a hazy cortex remains and dense nuclear
opacity is present; stage 4 - a mature cataract is observed as a
dense opacity in both cortex and nucleus [23].
Blood, lens collection, and processing: Blood was collected once a week from the retroorbital plexus for glucose
and insulin estimation. At the end of eight weeks, the animals
were sacrificed by CO2 asphyxiation and the lenses were dissected by the posterior approach and stored at -85 °C until
further analysis. A 10% lens homogenate was prepared from
three to five pooled lenses in a 50 mM phosphate buffer, pH
7.4. All the biochemical parameters were analyzed in the
soluble fraction of the lens homogenate (15,000x g at 4 °C)
except for lens malondialdehyde (MDA) and sorbitol, those
were determined in the total homogenate.
Clinical parameters: Serum glucose and insulin were
measured by the glucose oxidase-peroxidase method with a
commercial kit (Ozone Biomedicals Pvt. Ltd., New Delhi,
India) and by an RIA kit (BRIT-DAE, Mumbai, India), respectively.
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Figure 1. Delay of diabetic cataract in rats by Emblica and its tannoidenriched fraction. Cataract formation was monitored weekly by slitlamp microscope and the stage of cataract was scored according to
the classification described in the Methods section. Stages of cataract in each group were averaged at the given time and the average
stage of cataract was plotted as a function of time. Emblica (Group
IV) and its constituent tannoids (Group III) delayed the maturation
of diabetic cataract due to slow progression compared to untreated
diabetic rats (Group II). Lenses in control rats (Group I) were clear
during the experimental period.
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Biochemical estimations: Lens MDA was measured as
thiobarbituric acid reacting substances (TBARS) [29] and protein carbonyl content was determined according to reported
methods [30]. The activities of AR [22] and sorbitol dehydrogenase (SDH) [31], superoxide dismutase (SOD) [32], glutathione peroxidase (GPx) [33], and glutathione S-transferase
(GST) [34] were assayed according to the reported methods.
Sorbitol levels in the lens were estimated by enzymatic method
[35]. Total and soluble protein was analyzed by the Lowry
method with bovine serum albumin as a standard.
SDS-PAGE and size exclusion chromatography of lens
proteins: Subunit profile and cross-linking of soluble proteins were analyzed by SDS-PAGE under reducing conditions.
Crystallin distribution in the soluble protein fraction was evaluated by size exclusion chromatography according to previously reported methods [23].
Data analysis: One-way ANOVA was used for testing
statistical significance between groups of data and individual
pair difference was tested by means of Duncan’s multiplerange test. Heterogeneity of variance was tested by the nonparametric Mann Whitney test. A p<0.05 was considered significant.
RESULTS & DISCUSSION
Food intake and body weights: There was an increase in the
food intake in all the diabetic groups (II, III, and IV) compared with the control group (data not shown). Despite the
increased food intake, the body weight of diabetic (Group II)
animals was decreased when compared with nondiabetic controls (Group I). However, feeding of either tannoids or Emblica
to diabetic rats (Group III and IV) did not normalize body
weights to a significant extent (data not shown).

Cataract progression: The onset of cataract due to hyperglycemia was observed in diabetic animals after four weeks
of STZ injection. The average incidence of cataract was calculated and presented in Figure 1. Interestingly, there was a
delay in the onset of cataract in Group IV animals when compared to Group II. However, such a delay was not observed in
Group III animals. This observation indicates that the whole
Emblica was more effective than its tannoid fractions in delaying the onset of cataract. At the end of eight weeks, the
severity of cataracts was significantly lower in groups III and
IV than in Group II, indicating that the Emblica and its constituent tannoids delayed the maturation of diabetic cataract
due to slow progression. All the lenses in Group I during the
experiment period appeared to be normal and free of opacities
TABLE 1. THE EFFECT OF EMBLICA AND TANNOIDS ON MARKERS OF
THE POLYOL PATHWAY IN LENS
Enzyme
-------AR
SDH
Sorbitol

Group I
---------24.96±1.04
3.59±2.07
0.24±0.02

Group II
----------30.98±1.27*
3.57±1.00
5.74±0.77*

Group III
----------27.14±0.16#
3.35±1.02
3.63±0.47#

Group IV
----------27.55±1.69#
3.12±1.09
3.92±0.27#

Emblica (Group IV) and tannoids (Group III) are partially effective
against osmotic stress caused by hyperglycemia (Group II) with respect to AR activity and sorbitol levels. Group I: Control rats. The
data are the mean±SD (n=4). AR activity was expressed as µmoles
NADPH oxidized/h/100 mg protein. SDH activity was µmoles NADH
oxidized/h/100 mg protein. Sorbitol was expressed as µmoles/g lens.
The asterisk denotes that data are significantly different from Group
I and the sharp (hash mark) denotes that data are significantly different from Group II.

Figure 3. Protein carbonyl content in the soluble protein fraction of
lens. Protein carbonyl groups of soluble protein fraction of different
groups were assayed by reactivity to 2,4-DNPH as described in the
Methods section. Protein carbonyl content, a measure of oxidative
damage to proteins, increased in untreated diabetic (Group II) compared with controls (Group I). Emblica (Group IV) and its tannoids
(Group III) prevented the alterations in protein carbonyls. Data are
mean±SD (n=4). The asterisk above the bar denotes that data are
significantly different from Group I and the sharp (hash mark) denotes that data are significantly different from Group II.

Figure 2. Effect of Emblica and tannoids on lipid peroxidation in the
lens. Lipid peroxidation was assessed by estimation of TBARS in
the total lens homogenate. TBARS levels, a measure of lipid
peroxidation, increased in untreated diabetic (Group II) compared
with control (Group I). Emblica (Group IV) and its tannoids (Group
III) prevented the alterations in TBARS. Data are mean±SD (n=4).
The asterisk above the bar denotes that data are significantly different from Group I and the sharp (hash mark) denotes that data are
significantly different from Group II.
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(Figure 1) as were lenses from nondiabetic rats treated with
either Emblica or tannoids (data not shown). These data suggest that progression of lens abnormalities and maturation of
cataracts due to STZ-induced hyperglycemia were significantly
delayed with feeding of Emblica and its tannoids. The effect
was slightly more pronounced with Emblica treatment.
Blood glucose and insulin: Blood glucose was measured
weekly and insulin levels were measured at the end of the
experiment to test whether Emblica and its tannoids had a direct effect on STZ-induced hyperglycemia. As expected, blood
glucose levels were elevated and insulin levels were decreased
significantly in Group II compared to Group I [23]. However,
treatment with either Emblica or its tannoids did not reverse
the changes in blood glucose and insulin levels, indicating
that the Emblica and tannoids treatment had no effect on the
hyperglycemia (data not shown).
Polyol pathway: While the specific activity of AR, a key
enzyme of the polyol pathway, was significantly higher in
Group II than in Group I, SDH activity was not significantly
altered (Table 1). AR activity in lenses from animals treated
with Emblica and tannoids were intermediate to Groups I and
II, consistent with our previous observations on the in vitro
inhibition of human recombinant and rat lens AR by Emblica
tannoids [22]. Further, there was an increase of sorbitol levels
in Group II animals when compared to Group I (Table 1), which
was expected following activation of the polyol pathway in
diabetic lens. However, feeding of tannoids and Emblica resulted in a lower but incomplete normalization of diabetesinduced sorbitol accumulation (Table 1). Based on these results, it appears that Emblica and tannoids are partially effective against osmotic stress caused by hyperglycemia. These
results are consistent with the hypothesis that the delay of diabetic cataract by Emblica and its tannoids is related to inhibition of AR and of accumulation of sorbitol in the lens. Moreover, partial inhibition of AR and sorbitol accumulation brought
about by Emblica and its tannoids is in agreement with a delay and not a complete prevention of diabetic cataract.
Oxidative stress and the antioxidant system: There is accumulating evidence that oxidative stress contributes to the
development of diabetic cataract [12,36-38]. Recent studies
indicate that the polyol pathway may be related to hyperglyTABLE 2. ACTIVITIES OF SUPEROXIDE DISMUTASE, GLUTATHIONE
PEROXIDASE, AND GLUTATHIONE S-TRANSFERASE IN LENS
Enzyme
-----SOD
GPx
GST

Group I
---------26.81±0.62
17.31±0.52
24.82±0.55

Group II
----------36.88±6.95*
18.42±0.75*
22.18±0.48*

Group III
----------32.15±7.65#
17.84±0.40#
22.11±1.86

cemia-induced oxidative stress and there may be a metabolic
connection between the polyol pathway and oxidative stress
[12,39,40]. It was also reported that AR inhibitors reduce oxidative damage [12,40]. In the present study, we assessed oxidative stress by measuring TBARS, protein carbonyls, and
some of the antioxidant enzymes in the lens. Increased TBARS
levels in the untreated diabetic group (Group II) compared to
nondiabetic controls (Group I) indicate increased lipid
peroxidation in the lens due to hyperglycemia (Figure 2). Protein carbonyl content, a measure of oxidative damage to proteins, was also found to be increased in Group II compared to
Group I suggesting enhanced protein oxidation under hyperglycemic conditions (Figure 3). Interestingly, treatment with

Figure 4. The distribution profile of crystallins in the soluble fraction
of lens. The distribution profile of crystallins in the soluble fraction
of lens of different groups was monitored by size exclusion chromatography (SEC). Soluble protein (20 µl of a 1 mg/ml dilution in equilibration buffer) was loaded on TSK-G 2000 SW SEC column and
protein peaks were detected at 280 nm with a flow rate of 1 ml/min.
Peaks representing α-, β-, and γ-crystallins and high molecular weight
(HMW) fractions are indicated at their respective positions.
TABLE 3. PROTEIN CONTENT OF RAT LENS

Group IV
----------26.84±0.67#
18.77±0.20
23.37±0.35

Parameter
--------------------------Total protein (mg/g lens)
Soluble protein (mg/g lens)
Soluble protein (%)

Emblica (Group IV) and tannoids (Group III) treatment partially prevented the altered activities of antioxidant enzymes in untreated diabetic group (Group II). Group I: Control rats. The data are the
mean±SD (n=3). SOD activity is expressed as units/min/100 mg protein. The activity of GPx and GST is expressed as µmoles of NADPH
oxidized/h/100 mg protein and mmoles of CDNB-GSH conjugate
formed/h/100 mg protein, respectively. The asterisk denotes that data
are significantly different from Group I and the sharp (hash mark)
denotes that data are significantly different from Group II.

Group I
--------470±27.88
392±29.91
83.3

Group II
---------414±45.96*
209±46.00*
49.29

Group III
---------458±29.37#
330±46.00#
72.05

Group IV
---------467±36.05#
340±47.01#
71.43
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There was a significant decrease in both total and soluble protein in
untreated diabetic (Group II) compared with the control (Group I)
and Emblica (Group IV) and tannoids (Group III) prevented the loss
of total and soluble protein in the lens. The total and soluble protein
in the lens of different groups was estimated by the Lowry method
and the percentage soluble protein content was derived from the estimated values. The data are mean±SD (n=4). The asterisk denotes
that data are significantly different from Group I and the sharp (hash
mark) denotes that data are significantly different from Group II.
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Emblica and its tannoids prevented the alterations not only in
TBARS but also in protein carbonyls despite elevated glucose levels. Simultaneously, there was an increase in specific
activities of SOD, GPx, and a marginal decrease in GST in
lenses of Group II animals compared with Group I which further substantiates the role of oxidative stress in cataractogenesis
due to hyperglycemia (Table 2). Emblica and tannoids treatment partially prevented the altered activities of antioxidant
enzymes. These data clearly demonstrate that Emblica and
tannoids not only inhibited osmotic stress but also prevented
hyperglycemia-induced lenticular oxidative stress probably
due to the inhibition of the polyol pathway. Moreover, the
tannoid rich fraction of Emblica has been shown to exert antioxidant properties in stress-induced oxidative damage model
in rat brain [41,42].
TABLE 4. THE DISTRIBUTION OF CRYSTALLINS IN A SOLUBLE PROTEIN
FRACTION
Peak
--------------------α-Crystallin+HMW Peak
β-Crystallin
γ-Crystallin

Group I
------100
100
100

Group II
-------211
55
74

Group III
--------111
85
112

Group IV
-------102
93
110

Emblica (Group IV) and tannoids (Group III) treatment normalized
the altered crystallin distribution in untreated diabetic (Group II).
Group I: Control rats. Data are the average of three HPLC runs for
the area under the curve. The relative percentage of peaks on the
SEC column in untreated and treated diabetic groups was calculated
by considering the area under the curve for the respective peak in
Group I as 100%.

©2007 Molecular Vision

Protein crosslinks and insolubilization: During the development of cataract, alterations in lens proteins and
insolubilization have been considered to be the major change
that results in lens opacification. Therefore, we analyzed the
total and soluble protein content in all the groups. There was a
significant decrease in both total and soluble protein in Group
II compared with the control group (Table 3). This could be
due to a partial leakage of proteins into the aqueous humor.
Feeding of Emblica and tannoids to the diabetic rats prevented
the loss of total and soluble protein in the lens. The prevention
of loss in lens soluble protein in STZ-treated rats was well
correlated with the delay of maturation of cataract in those
groups (Figure 1). We have also studied the possible alterations or modifications in the crystallin profile due to diabetes-induced hyperglycemia by size-exclusion chromatography
(SEC) as well as by SDS-PAGE. The distribution profiles of
Group II lens proteins following SEC showed a decrease in βand γ-crystallin peaks and an increase in the α-crystallin-associated high molecular weight (HMW) aggregate peak when
compared to Group I (Figure 4; Table 4). The decrease in βand γ-crystallins suggests protein degradation in diabetic cataract lens. The formation of HMW aggregates may be due to
either cross-linking of degraded products or some other
changes. Similar changes were also observed in our previous
study [23]. By SDS-PAGE analysis, a set of protein bands
corresponding toa molecular weight of about 45,000 Da was
observed more prominently in Group II lenses as compared to
the other groups (Figure 5). We hypothesize that these bands
represent crosslinked proteins induced in the hyperglycemic
lens. It is interesting to note that changes in the crystallins due
to diabetes were minimized by feeding with Emblica and
tannoids (Figure 4, Figure 5, and Table 4). Further studies are
required to determine whether these changes might be the result of direct inhibition of polyol pathway or the result of an
indirect effect involving reduced polyol pathway-mediated
oxidative damage.
In this study, we demonstrated that feeding of Emblica or
its constituent tannoids could delay the progression of diabetic cataract in rats. Enhanced glucose flux through the polyol
pathway and increased sorbitol and fructose accumulation has
been implicated in diabetes-induced cataract formation [43].
In our study, we observed increased specific activity of AR
with simultaneous increased sorbitol levels in untreated diabetic rats compared with control animals. Interestingly, feeding of Emblica at a 2% level and tannoids at a 0.2% level
resulted in decreased formation of sorbitol, presumably as a
result of AR inhibition. Although multiple mechanisms may
contribute to these effects, the antiosmotic effect of Emblica
appears to be the predominant mechanism of action. Though
there are reports on hypoglycemic activity of Emblica [25], in
our study, we did not observe such an effect. One of the important observations of this study was that Emblica delayed
the progression and maturation of cataract despite elevated
levels of glucose. While the levels of Emblica and tannoids
used in the study were based on a pilot study involving a small
number of rats, it may be feasible to observe more pronounced
effects with still higher doses. If that is achieved, delay of

Figure 5. Subunit profile and protein cross-linking of the soluble fraction of lens. Soluble lens protein was loaded onto a 12% polyacrylamide gel under reducing conditions. Lane 1: Molecular weight markers, lane 2: Control (Group I), lane 3: Untreated diabetic (Group II),
lane 4: Tannoid fed diabetic (Group III), lane 5: Emblica fed diabetic
(Group IV), and HMW: High molecular weight cross links. Arrows
indicate cross-linked proteins in untreated diabetic rat lens (Lane 3),
which were reduced in the Emblica and tannoid treated groups.
1295
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